News Releases

Medtronic Diabetes resolves warning letter, clearing path for future innovations

-April 25, 2023

DUBLIN, April 25, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) lifted the warning letter received at the company's Diabetes headquarters in Northridge, California, in December 2021. This follows on the heels of last week's FDA approval of the MiniMed^™ 780G system, the world's first and only automated insulin delivery system with meal detection technology^* that provides automatic adjustments and corrections^† to glucose levels every 5 minutes.^§

FDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§

-April 21, 2023

DUBLIN, April 21, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 780G system with the Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology^‡. This milestone marks the approval of the only system with meal detection technology^* that provides automatic adjustments and corrections^† to sugar levels every 5 minutes^§. The system provides insulin to help account for when users occasionally forget to bolus or underestimates the number of carbs in their meal.

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.

-November 15, 2022

DUBLIN, Nov. 15, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and only infusion set labelled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.

Medtronic leverages data science to launch first-of-its-kind personalized insights program for people living with diabetes

-October 18, 2022

DUBLIN, Oct. 18, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing.

Medtronic Commends CMS on Proposed Rule to Expand Medicare Coverage for All CGMs

-October 28, 2020

October 28, 2020 – On October 27th, the Centers for Medicare & Medicaid Services (CMS) announced proposed new changes that, if finalized, would expand Medicare coverage for Continuous Glucose Monitors (CGMs) that provide critical information on glucose levels to help people with diabetes better manage their disease. We are very encouraged by CMS’s proposed rule and commend the agency on taking action to help more people with diabetes.

View all announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Cho
Sr Director, Global Communications
818-576-5014
janet.cho@medtronic.com

Ashley Patterson
818-576-3025
ashley.a.patterson@medtronic.com

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits